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Many protein-protein interactions in cells are medi-
ated by functional domains that recognize and bind
to motifs containing phosphorylated serine and
threonine residues. To create small molecules that
inhibit such interactions, we developedmethodology
for the synthesis of a prodrug that generates a phos-
phoserine peptidomimetic in cells. For this study,
we synthesized a small molecule inhibitor of 14-3-3
proteins that incorporates a nonhydrolyzable difluor-
omethylenephosphoserine prodrug moiety. The pro-
drug is cytotoxic at low micromolar concentrations
when applied to cancer cells and induces caspase
activation resulting in apoptosis. The prodrug
reverses the 14-3-3-mediated inhibition of FOXO3a
resulting from its phosphorylation by Akt1 in a
concentration-dependent manner that correlates
well with its ability to inhibit cell growth. Thismethod-
ology can be applied to target a variety of proteins
containing phosphoserine and other phosphoamino
acid binding domains.
INTRODUCTION
The effort to target protein-protein interactions (PPIs) has
increased in recent years because of reports revealing the
importance of many such interactions in the development and
progression of cancer. The arguments against targeting PPIs
with small molecules include the often large protein surface
areas involved and the large number of residues that interact
and contribute to the free energy of binding (Lo Conte et al.,
1999). The dogma has been that small molecules cannot repli-
cate these various interactions and still maintain the advantages
of a small molecule. Many PPIs are mediated through phosphor-
ylation sites that interact with phosphotyrosine or phosphoser-
ine/threonine recognition motifs. The free energy of binding in
these cases is contributed primarily by the phosphate-contain-
ing residue (Bradshaw et al., 1999). This important aspect makes
these targets much more amenable to inhibition with small
molecules. However, developing small molecule inhibitors of
these sites presents a number of serious obstacles. The intracel-
lular delivery of drugs that contain the necessary doubly charged764 Chemistry & Biology 19, 764–771, June 22, 2012 ª2012 Elsevierphosphate group is difficult because of the lipophilic cell
membrane (Xie et al., 2003). Once the drug enters the cell, it is
subject to dephosphorylation by phosphatases, rendering it
inactive.
Numerous strategies have been reported for the design of
phosphate and phosphonate prodrugs, most of them intended
to increase oral bioavailability of the highly charged group.
Pivaloxymethyl (POM) esters have been utilized extensively in
the design of nucleotide prodrugs, and this strategy was used
recently to enhance the cellular permeability of a phosphonate-
based inhibitor of the mitotic regulator Pin1 (Zhao and Etzkorn,
2007). Cyclic phosphotriesters incorporating serine-containing
peptides have also been used to enhance oral bioavailability
and cell permeability for antiviral acyclonucleoside phospho-
nates such as Cidofovir (Eriksson et al., 2008). We have devel-
oped a strategy for the preparation of phosphate and phospho-
nate prodrugs that are specifically activated intracellularly. The
phosphate bridging oxygen was replaced by the difluoromethy-
lene isostere to prevent phosphatase cleavage of the phosphate
group under physiological conditions. This moiety has the
appropriate pKa to deliver a doubly charged phosphate mimetic
to the binding site (Zheng et al., 2005). This methodology has
been shown to be successful in the development of nucleotide
prodrugs (Freel Meyers et al., 2000; Tobias and Borch, 2001),
inhibitors of phosphotyrosine binding proteins containing Src
homology 2 (SH2) domains (Garrido-Hernandez et al., 2006),
and inhibitors of protein tyrosine phosphatase 1B (PTP1B)
(Boutselis et al., 2007).
We were interested in assessing whether this prodrug tech-
nology was applicable to the development of phosphoserine
mimetics. Historically, phosphoserine/threonine sites were
thought to function allosterically in contrast to phosphotyrosine
sites that often mediate PPIs (Yaffe and Smerdon, 2001). In
recent years, several important PPIs have been discovered
that are mediated through phosphorylation of serines or threo-
nines. These include PPIs involving 14-3-3 proteins, WW
domains, Forkhead-associated (FHA) domains, and the WD40
and LRR domains of F-box proteins (Yaffe and Smerdon,
2001). For our initial efforts, we focused on 14-3-3 proteins.
This highly conserved and ubiquitously expressed family of
proteins is involved in many vital cellular processes including
signal transduction, apoptosis, cell-cycle regulation, growth,
and development (Yaffe and Smerdon, 2001). There are seven
different isoforms in humans that interact to form homo or
heterodimers. Many of the functions of the 14-3-3 proteins are
regulated by the phosphorylation of their binding partnersLtd All rights reserved
Figure 1. Synthesis of the a,a-Difluorome-
thyenephosphoserine Mimetic
Reagents and conditions: (a) MeSCF2P(O)(Oi-Pr)2,
t-BuLi, THF/HMPA, 78C, 55%; or (b)
HCF2P(O)(OEt)2, LDA, THF/HMPA, 78C, 75%;
(c) Boc2O, DMAP, THF; (d) Mg, MeOH, 91%; (e)
conc HCl, MeOH; (f) FmocCl, DIPEA, 92%; (g)
Jones reagent, acetone, 25C, 75%.
See Figure S1.
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identified: RSXpSXP (mode 1) and RXXXpSXP (mode 2) (Yaffe
et al., 1997). 14-3-3 proteins bind to many targets including the
tumor suppressor p53, Raf family kinases, FOXO transcription
factors, the proapoptotic protein BAD, andCdc25 phosphatases
through these recognition sequences. Upon binding, 14-3-3 acts
as an adaptor, leading to changes in enzymatic activity or
subcellular localization (Aitken, 2006). These characteristics
make the 14-3-3 family an interesting target for cancer therapeu-
tics (Hermeking, 2003).
Although it has been established that 14-3-3 proteins are
involved in several serious disorders, much about the details of
these mechanisms is unknown. The difluoromethylenephospho-
serine moiety may be used as a biological tool to construct
a constitutive pCF2-Ser modification in a native protein or in
the synthesis of small peptides/peptidomimetics to mimic
protein binding partners. Phosphatase-resistant phosphoserine
mimetics are now achievable, allowing for site-specific phos-
phorylation studies and examination of downstream conse-
quences of this event (Panigrahi et al., 2009). The utility of the
phosphoserine mimetic has been demonstrated by Cole and
coworkers (Zheng et al., 2005; Szewczuk et al., 2008), who
were interested in examining the regulation of arylalkylamine
N-acetyltransferase (AANAT), which is responsible for cycle
regulation of melatonin (Klein, 2007). Phosphorylation at Ser-
205 was proposed to modulate the acyltransferase activity
of AANAT (Zheng et al., 2005). The protein was hypothesized
to be shielded from proteosomal proteolysis by association to
14-3-3 z through pSer-205. The Cole group synthesized the
octapeptide containing a difluoromethyl phosphoserine mimetic
and used their EPL technology to look for an interaction between
pSer-205 AANAT and its 14-3-3 z binding partner (Szewczuk
et al., 2008). Through this construct they were able to demon-
strate that phosphorylation at this site results in binding to 14-
3-3 z and enhances cellular stability of AANAT protein. This
example demonstrates that this unnatural amino acid is an
invaluable tool for the dissection of biological pathways.
Until recently, only small molecule stabilizers of 14-3-3 PPIs
were known. Fusicoccin and cotylenin have been used success-
fully to study the role that 14-3-3 plays in plant physiology and
cancer (Ottmann et al., 2007). Another recent screen has
identified more PPI stabilizers, but inhibitors of 14-3-3 PPIs are
still scarce (Rose et al., 2010). In this study, we describe the
synthesis and characterization of a nonhydrolyzable phospho-
serine peptidomimetic prodrug. This molecule, targeted against
14-3-3 family proteins, induces apoptosis in leukemia cells and
reverses the 14-3-3-dependent inhibition of the proapoptotic
transcription factor FOXO3a. The strategy described here canChemistry & Biology 19,be applied to create a variety of inhibitors of important protein
targets involved in phosphorylation-dependent interactions.
RESULTS AND DISCUSSION
Synthesis of Phosphoserine Mimetic Prodrug
When we began to design our synthesis, we considered the
construction of a,a-difluoromethylenephosphoserine analogs
that had been pioneered by Berkowitz and studied by other
groups (Berkowitz et al., 1994, 1996; Otaka et al., 1995; Yoko-
matsu et al., 1996; Kawamoto and Campbell, 1997). There are
currently three general strategies known for accessing this
moiety: displacement of a primary triflate with phosphonodifluor-
omethyl carbanion (Berkowitz et al., 1994, 1996; Yokomatsu
et al., 1996), reaction of phosphonodifluoromethyl carbanion
with Garner’s aldehyde (Otaka et al., 1995), and transition
metal-mediated alkene addition with a Cu reagent (Kawamoto
and Campbell, 1997). Alternatively, an optically pure aziridine is
a useful synthon for the preparation of chiral amines, amino
alcohols, and amino acids. Synthesis of an enantiomerically
pure amino alcohol moiety could be achieved by selective
ring opening of chiral aziridines with various nucleophiles (Hu,
2004). Oxirane ring opening by a,a-difluoromethylenephospho-
nate anion to furnish g-hydroxy-a,a-difluoromethylenephospho-
nates has been reported (Ozouf et al., 2004; Pajkert et al., 2008);
however, aziridine ring opening with the same anion has not
been reported to date. Thus, we speculated that the reaction
of chiral aziridine with a,a-difluoromethylene diethylphospho-
nate anion might provide facile access to the desired nonhydro-
lyzable phosphoserine core structure.
We recently reported the preparation of enantiomerically en-
riched aziridines via enzymatic desymmetrization of prochiral
N-protected serinol (Choi and Borch, 2007). WithN-Ts protected
chiral aziridine 1 in hand (Figure 1), ring opening of the aziridine
was investigated (Fujii et al., 1994; Bergmeier and Seth, 1997).
Addition of the magnesium (Waschbu¨sch et al., 1997) or
cadmium (Qiu and Burton, 1996) reagent prepared from diethyl
bromodifluoromethyl phosphonate was investigated without
success. The anion prepared by reaction of diisopropyl methyl-
thiodifluoromethylenephosphonate and t-butyllithium (Henry-
dit-Quesnel et al., 2003) reacted with 1 to give the desired
product 2a in 55% yield (Figure 1). However, because of the
difficult preparation of the methylthio reagent and subsequent
problems with selective cleavage of the isopropyl ester, we
turned our attention to the generation and reaction of the lithium
anion via direct deprotonation of the difluoromethylenephosph-
onate. (Berkowitz et al., 1996) Extensive investigation of bases,
solvents and reaction conditions gave only trace amounts of764–771, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 765
Figure 2. Synthesis of the Phosphoserine Phosphonamidate Prodrug
Reagents and conditions: (a) Ac2O, DIPEA, DMAP (cat.), 97%; (b)TMSI; (c) oxalyl chloride; (d) 4-chloro-N-methylbutan-1-amine hydrochloride, DIPEA, 54%; (e)
(5-nitrofuran-2-yl) methanol, LHMDS, THF, 78C, 55%; (f) K2CO3, MeOH, 4C, 70%; (g) Jones reagent, 25C, acetone, 70%.
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diethyl difluoromethylenephosphonate with LDA in THF/HMPA
followed by addition of aziridine 1. Because of the instability of
the lithium anion at higher temperature, the reaction was main-
tained at 78C overnight, and ring-opened product 2b was
obtained in 75% yield along with a small amount of recovered
starting material. HMPA was the only cosolvent that provided
reasonable yields of product, presumably because of its unique
features as a dipolar aprotic solvent. Direct conversion of the
tosyl to the Boc protecting group of 2 was achieved via the
doubly protectedN-BocN-Ts amine; brief sonication in the pres-
ence of magnesium powder in anhydrous methanol (Nyasse
et al., 1997) smoothly furnished N-Boc protected amine 3.
Removal of both TBS and Boc protecting groups was accom-
plished, and the resulting amine was converted to its Fmoc
analog 4. The Fmoc protected phosphonoamino acid 5 was
accessible via Jones oxidation of alcohol 4. To continue the pro-
drug synthesis (Figure 2), the hydroxyl group in 4 was converted
to the acetate 6 (Otaka et al., 1995). The diethyl phosphonate 6
was converted to the phosphonamidate 8 using the same
method previously reported for the phosphotyrosine mimetics
(Boutselis et al., 2007). Briefly, the phosphonate was converted
to the phosphonyl dichloride by successive treatment with
TMSI and oxalyl chloride, reaction with methyl chlorobutylamine
gave phosphonamidic chloride 7, and reaction of 7 with nitrofur-
furyl alcohol and base afforded phosphoramidate 8. Careful de-
protection of acetate 8 with cold potassium carbonate followed
by oxidation of alcohol 9 using Jones reagent gave the desired
phosphoserine prodrug 10. This route obviates the need for
chiral starting materials and is highly efficient for preparation of
the prodrug.
Synthesis of 14-3-3 Inhibitor
While this work was in progress, the identification of a small
molecule 14-3-3 inhibitor was reported (Wu et al., 2010). The
inhibitor, compound 19b (Figure 5), is a phosphoserine peptido-
mimetic that was identified using a small molecule microarray766 Chemistry & Biology 19, 764–771, June 22, 2012 ª2012 Elsevier(SMM) screen. It showed promising results in cell-free assays
and appeared to be an appropriate candidate to demonstrate
proof of concept for the phosphoserine prodrug. The prodrug
15 (Figure 3) was synthesized using phosphoserine prodrug
precursor 10. PYBOP coupling of 10 with tyramine furnished
13; removal of the Fmoc protecting group afforded free amine
14, which was coupled with 11 (Figure 4) using PYBOP to furnish
the desired inhibitor 15. In order to have the corresponding free
ligand available for comparative cell-based studies, compound
19awas prepared (Figure 5). Tyramine was coupled with 5 using
PyBOP, followed by deprotection of Fmoc with DBU to give
coupling product 16. Because the azide in coupling partner 12
was unstable in the presence of TMSI, the diethyl phosphonate
was converted to phosphonic acid 18 prior to coupling. Reaction
of 11 and 18 using standard peptide coupling conditions was
problematic, so acid 11 was transformed to the NHS-ester 12
(Figure 4). Reaction of amine 18 and activated ester 12 in the
presence of triethylamine gave the free ligand 19a.
This class of prodrug readily enters cells and is metabolically
activated intracellularly to generate the active phosphate/phos-
phonate ligand (Garrido-Hernandez et al., 2006; Boutselis
et al., 2007). Themechanism of prodrug activation for compound
15 is shown in Figure 6. Upon entry into the cell, the nitrofurfuryl
group is removed under physiological conditions via enzymatic
reduction and spontaneous expulsion to furnish phosphonami-
date anion A. Intramolecular cyclization of A results in interme-
diateB, which hydrolyzes spontaneously to furnish phosphonate
product 19a.
Biological Evaluation of 14-3-3 Inhibitor
We measured the growth inhibitory activity of the prodrug and
the active ligand in human DG75 leukemia cells. After treatment
with compound 15 or compound 19a for 48 hr, the number of
live cells was counted and compared to treatment with DMSO
alone. The results are shown in Figure 7A. Compound 15 was
a potent inhibitor with an IC50 value of 5 mM; however, the free
phosphonate 19a showed no meaningful growth inhibition atLtd All rights reserved
Figure 3. Synthesis of the 14-3-3 Inhibitor Prodrug
Reagents and conditions: (a) 4-(2-aminoethyl)phenol, PYBOP, DIPEA, 80%; (b) DBU, DCM, 58%; (c) 11, PYBOP, DIPEA, DMF, 50%.
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>90% at concentrations of 15 up to 5 mM but decreased rapidly
at higher concentrations, suggesting that 15was highly cytotoxic
at concentrations >10 mM. These results are consistent with the
facile uptake of the prodrug as compared to the highly charged
phosphonate ligand.
The potential cytotoxic effects of compound 15 were investi-
gated by monitoring the cleavage of poly (ADP-ribose) poly-
merase (PARP), a well-known caspase substrate. DG75 cells
were treated with increasing concentrations of 15 for 24 hr.
The cells were lysed and the amounts of full-length and cleaved
PARP were detected by western blot. Staurosporine (STS) was
chosen as the positive control; the results are shown in Figure 7B.
Significant PARP cleavage was observed at a prodrug concen-
tration of 12 mM, suggesting that the cytotoxicity of prodrug 15
results from induction of apoptosis.
To confirm a direct involvement of 14-3-3 proteins in the action
of 15, we developed an assay to monitor the 14-3-3-dependent
inhibition of FOXO transcription factors. FOXO3a is one of the
Forkhead transcription factors that is phosphorylated by Akt1,
and the phosphorylated protein binds to 14-3-3. This binding
facilitates the nuclear export of FOXO3a by exposing nuclear
export sequences and its retention in the cytoplasm by masking
nuclear localization sequences. This regulation by the 14-3-3
proteins allowed us to monitor the inhibition of 14-3-3 directly
through a FOXO3a-driven luciferase reporter assay. In thisFigure 4. Synthesis of the Activated NHS-Ester Moiety
Reagents and conditions: (a) EtOCOCH2NH2$HCl, PYBOP, DIPEA, 87%; (b) LiO
Chemistry & Biology 19,assay, we transfected DG75 cells with plasmids coding for
FOXO3a and/or Akt1 along with two luciferase reporter
constructs: FOXO3a-luciferase and, as a control for transfection
efficiency, TK Renilla-luciferase construct. After recovery, cells
were treated with increasing concentrations of compound 15
for 12 hr. Luminescence measurements were carried out using
the Dual-Glo Luciferase assay system (Promega). The results
are shown in Figure 7C. The ectopic expression of FOXO3a led
to a substantial increase in FOXO3a-mediated gene transcrip-
tion, which was inhibited upon cotransfection of Akt1 as ex-
pected. FOXO3a stimulated transcription was recovered in
a dose-dependent manner by treatment of cells with increasing
concentrations of compound 15, consistent with inhibition of the
14-3-3-mediated retention of FOXO3a in the cytoplasm. As
a control, cell lysates from this experiment were analyzed by
western blot, revealing that the total amount of FOXO3a and
Akt1 is independent of treatment with 15 (Figure S1 available
online). Concentrations of 15 in excess of 8 mM resulted in
substantial cytotoxicity, so the effects of higher doses could
not be assessed. However, the concentration of 15 required to
recover 50% of the FOXO3a-induced gene expression was
consistent with the IC50 value for growth inhibition, further sug-
gesting that the cytotoxicity of 15 is a function of its ability to
bind 14-3-3.
To demonstrate that the effect of 15 on FOXO3a reporter
activity results from the direct interaction of 19a with theH, THF/H2O (3:1), 83%; (c) N-hydroxysuccinimide, THF, DIC, 68%.
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Figure 5. Synthesis of the 14-3-3 Inhibitor Ligand
Reagents and conditions: (a) 4-(2-aminoethyl)phenol, PYBOP, DIPEA, 86%; (b) DBU,DCM, 88%; (c) TMSI, then water, 84%; (d) 12, water/acetone, Et, 69%.
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Immobilized 14-3-3 t was incubated with DG75 cell lysate that
had been transfected with FOXO3a and Akt1; this incubation
produced an immobilized 14-3-3/FOXO3a complex. The
complex was then incubated with different concentrations of
19a for 1 hr. The bound proteins were then subjected to SDS-
PAGE, and the amount of FOXO3a remaining on the beads
following treatment with 19a was analyzed by western blot.
The results are shown in Figure 7D; a concentration-dependent
disruption of the 14-3-3/FOXO3a complex when the beads
were treated with 19a was observed. When the complex was
treated with prodrug 15 (24 mM), there was no change in FOXO3a
levels relative to the DMSO control (data not shown).
Wu et. al. reported that phosphate 19b binds to 14-3-3 with
high affinity and is cell permeable. However, much higherFigure 6. Prodrug Activation Mechanism
768 Chemistry & Biology 19, 764–771, June 22, 2012 ª2012 Elsevierconcentrations (100 mM) were required to see effects in cells
than are needed in cell-free assays (5 mM). In contrast, the pro-
drug 15 described here exhibits cellular effects at concentrations
that are comparable with those used in cell-free assays
measuring PARP cleavage and FOXO3a-induced gene expres-
sion, suggesting that the prodrug increases significantly the
intracellular delivery of the ligand 19a.
In summary, we have developed and executed a strategy for
the design, synthesis, and characterization of a class of small
molecule prodrug inhibitors of protein-protein interactions. The
successful design of deliverable, stable phosphoserinemimetics
has implications not only for the development of therapeutic
agents targeting 14-3-3 proteins, but also for the development
of small molecules that interdict other phosphoserine and phos-
phothreonine-binding domains.Ltd All rights reserved
Figure 7. Biological Analysis of a 14-3-3
Inhibitor
(A) Growth inhibition of DG75 cells. DG75 cells
were treated with 1.5, 3, 6, 12, and 24 mM 15 for
48 hr. DMSO was used as a negative control.
Live cells were counted by exclusion of trypan
blue using the BioRad automated cell counter.
Error bars report SEM for three separate experi-
ments.
(B) Activation of apoptotic marker upon treatment
with 15. DG75 cells were treated with 15 at 3, 6,
and 12 mM for 24 hr. Treatment with DMSO and
Staurosporin (STS, 100 nM) provided negative and
positive controls, respectively. The levels of PARP
in full-length and cleaved forms were analyzed by
western blot.
(C) Effect of 15 on the cellular 14-3-3/FOXO3a
interaction. DG75 cells were transfected with
plasmids for the transcription factor FOXO3a,
Akt1, FOXO3a-luciferase, and TK-Renilla lucif-
erase. After a 12 hr recovery, cells were treated
with 1, 3, 6, and 8 mM 15 for 12 hr. Luminescence
measurements were made and presented as
a percentage of luminescence measured in cells
expressing FOXO3a. The bars report mean ± SE
for three separate experiments.
(D) Effect of 19a on the molecular 14-3-3/FOXO3a
interaction. Immobilized 14-3-3 t was incubated
with DG75 cell lysates which were transiently
transfected with FOXO3a and Akt1. The immobilized 14-3-3/FOXO3a complex was incubated with 3, 12, or 24 mM 19a for one hour. The amount of FOXO3a
remaining on the beads was eluted and analyzed by western blot. The bars report mean ± SE for three separate experiments.
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A facile and high-yield synthesis of a nonhydrolyzable
phosphoserine mimetic prodrug has been developed that
provides efficient intracellular delivery of the highly charged
phosphonoserine moiety. The difluoromethylenephospho-
serine prodrug can be readily incorporated into other
phosphoserine mimetics, providing a unique avenue to the
investigation of proteins that are regulated by phosphoser-
ine recognition sites. The utility of this strategy was demon-
strated in the synthesis of a low micromolar inhibitor of
14-3-3 family proteins that exhibited exciting biological
results in cell-based assays.
EXPERIMENTAL PROCEDURES
Cell Culture
DG75 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine
serum, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 IU/ml penicillin
G, and 100 mg/ml streptomycin.
Growth Inhibition Assay
DG75 cells at 13 105 cells/ml were aliquotted in a 96-well plate with 100 ml per
well. Serial dilution (1 ml) of stock solutions of 15 in DMSO, 19a in DMSO, or
DMSO alone was added to each well to reach the desired final concentration.
The plate was then incubated at 37C at 5% CO2 for 48 hr. Live cells, as
determined by trypan blue exclusion, were counted using a Bio-Rad TC10
automated cell counter. The number of live cells in the drug-treated wells
was compared to those in wells that were treated with DMSO.
PARP Cleavage Assay
DG75 cells (13 106 cells/ml) were treated with DMSO, prodrug 15, or STS for
24 hr. The cells were harvested and washed twice with PBS. Cells were lysedChemistry & Biology 19,at 0C for 15 min in buffer containing 25 mM HEPES (pH 7.2), 150 mM NaCl,
1% Nonidet P-40, 10 mg/ml aprotinin, and 10 mg/ml leupeptin. Supernatants
from a 5 min centrifugation at 4000 3 g were separated by SDS-polyacryl-
amide gel electrophoresis and analyzed by western blot to determine the
amount of full-length and cleaved PARP. Rabbit antibody against PARP was
purchased from Cell Signaling Technology.
FOXO3a-Luciferase Assay
DG75 cells (8 3 107; 1 3 107 cells per treatment) were transfected with 10 mg
FOXO3a-Luciferase, 20 mg FOXO3a, 20 mg Akt1, and/or 2 mg TK-Renilla
Luciferase plasmids by elecotroporation (240 V, 960 mF). The cells were
allowed to recover on ice for 15 min. The cells were then diluted in 10 ml
FBS-containing RPMI media and allowed to incubate at 37C in 5%CO2. After
12 hr, prodrug 15 in DMSO was added at a final concentration of 1, 3, 6, and
8 mM. After incubating for another 12 hr, the cells were counted, resuspended,
and plated at 13 106 cells/ml. The cells were harvested 6 hr later and analyzed
for both firefly and Renilla luciferase activities using the Dual-Glo luciferase
assay system (Promega). The FOXO3a reporter activities were normalized
against those of the TK-Renilla luciferase internal controls.
Immobilized 14-3-3 t Binding Assay
GST-14-3-3 twas expressed in bacteria and bound to glutathione-Sepharose
beads. DG75 cells (1 3 107) were transfected with 20 mg FOXO3a and 20 mg
Akt1 expression plasmids by electroporation. The cells were allowed to
recover on ice for 15 min. The cells were then diluted in 10 ml FBS-containing
RPMI media and allowed to incubate at 37C in 5% CO2. After incubating for
24 hr, the cells were harvested and lysed in NP40 lysis buffer for 15 min on ice.
Aliquots of the lysate were incubated with immobilized 14-3-3 t for one hour at
4C. After incubation, the lysate was removed and the beads were washed
with NP40 lysis buffer two times. NP40 lysis buffer (200 ml) was added to
the beads followed by 2 ml DMSO or 19a in DMSO. This mixture was allowed
to incubate for one hour at 4C. Lysate was removed and the beads were
washed two times with lysis buffer. Bound proteins were separated by SDS-
PAGE and detected by western blotting using the FOXO3a antibody (Cell
Signaling).764–771, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 769
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